MARKET INTELLIGENCE·M&A
Eli Lilly's $2.8 Billion AtaiBeckley Acquisition Validates Psychedelics for Depression, Reshaping Neuroscience Market
Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, with an initial $2.8 billion equity value, marks a pivotal moment for psychedelic-based therapies. This strategic move diversifies Lilly's neuroscience portfolio, spearheaded by BPL-003 for treatment-resistant depression. It signals major pharmaceutical validation, compelling procurement and business development leaders to re-evaluate emerging drug pipelines and market access strategies in this rapidly evolving sector.
90-Day Activity